Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Supplemental Figure 1. Fold increase in viability EC50 values for PI3Ki-A/D relative to GDC-0941 in a full panel of 102 solid tumor lines binned by tissue type and PTEN status. Supplemental Figure 2. In vivo effects on body weight of GDC-0941 and PI3KiA/D. MCF7.1 breast tumor and NCI-PC3 prostate cells were implanted subcutaneously in the hind flank of female athymic nu/nu (nude) mice. Tumor-bearing mice were dosed orally with either vehicle (0.5% methylcellulose/0.2% Tween-80), 75 mg/kg GDC-0941 or 75 mg/kg PI3KiA/D for 21 or 14 continuous days (MCF7.1 or NCI-PC3, respectively). Supplemental Figure 3. Comparison of viability EC50 values (μM) of 99 solid tumor lines dosed with GDC-0941or PI3Ki-A/D binned by PIK3CA mutational status and PTEN status (The three dual PIKC3A mutant and PTEN negative lines were excluded for this analysis). Supplemental Table 1. Table of breast cancer cell lines. PIK3CA status, PTEN status, and viability EC50 values (μM) for GDC-0941 and PI3Ki-A/D. Supplemental Table 2. Table of colon cancer cell lines. PIK3CA status, PTEN status, and viability EC50 values (μM) for GDC-0941 and PI3Ki-A/D. Supplemental Table 3. Table of glioma cancer cell lines. PIK3CA status, PTEN status, and viability EC50 values (μM) for GDC-0941 and PI3Ki-A/D. Supplemental Table 4. Table of non-small cell lung cancer cell lines. PIK3CA status, PTEN status, and viability EC50 values (μM) for GDC-0941 and PI3Ki-A/D. Supplemental Table 5. Table of melanoma cancer cell lines. PIK3CA status, PTEN status, and viability EC50 values (μM) for GDC-0941 and PI3Ki-A/D. Supplemental Table 6. Table of ovarian cancer cell lines. PIK3CA status, PTEN status, and viability EC50 values (μM) for GDC-0941 and PI3Ki-A/D. Supplemental Table 7. Table of prostate cancer cell lines. PIK3CA status, PTEN status, and viability EC50 values (μM) for GDC-0941 and PI3Ki-A/D. Supplemental Table 8. Table of tumor drug levels. Drug concentrations were measured in MCF7.1 breast tumor xenografts (A) and NCI-PC3 prostate tumor xenografts (B) by a LC/MS/MS assay and the lower limits of quantitation (LLOQ) for detectable drug levels was 0.005 μM.